Sareum Holdings Plc · LSE:SAR
Sareum — FY2025 Earnings Presentation
20 slides from Sareum's earnings presentation, Oct 23, 2025
Slide 1: Preliminary Results for the Year Ended 30 June 2025
Preliminary Results for the Year Ended 30 June 2025 23 October, 2025 Dr Stephen Parker, Executive Chairman Dr Tim Mitchell, COO & Co-founder Dr John Reader, CSO & Co-founder
Slide 2: Disclaimer
DISCLAIMER The information contained in this document (“Presentation”) is directed at (i) members or creditors of a corporate body within the meaning of Article 43 of the Financial Services and Markets Act 2000 (Financial Promotions) Order 2005, as amended ("Order"), (ii) persons who have profession
Slide 3: Sareum: advancing next-generation therapies for autoimmune diseases and cancer
Sareum: advancing next-generation therapies for autoimmune diseases and cancer • Sareum is a clinical-stage company developing oral, small- molecule kinase inhibitors. • Focus on TYK2/JAK pathways for autoimmune diseases, and DNA-damage repair for cancer. • Sareum aims to take its drug candidates th
Slide 4: Progressing our pipeline - development
Progressing our pipeline - development Programme Discovery Preclinical Clinical Phase 1 Clinical Phase 2 Clinical Phase 3 Potential Indications Psoriasis, RA, Lupus, IBD TYK2 / JAK1 Autoimmune disease SDC-1801 Acute respiratory symptoms of viral infections / Covid-19 Cancer immunotherapy SDC-1802 T-
Slide 5: TYK2 / JAK1 inhibitor programmes
TYK2 / JAK1 inhibitor programmes Proprietary pipeline
Slide 6: Supportive commercial environment, validated science
Supportive commercial environment, validated science VALIDATED SCIENCE COMMERCIAL POTENTIAL BROAD POTENTIAL APPLICABILITY Approval of BMS’s TYK2 inhibitor Psoriasis affects > 125m Sotyktu (TYK2i) is approved for Sotyktu (deucravacitinib) without worldwide and had an approx. psoriasis and psoriatic a
Slide 7: SDC-1801: differentiated mechanism, strong safety profile
SDC-1801: differentiated mechanism, strong safety profile Programme Overview • SDC-1801 is a selective TYK2/JAK1 inhibitor being developed for autoimmune diseases, with an initial focus on psoriasis. • Positive topline data from the Phase 1 clinical trial (single and multiple ascending dose) demonst
Slide 8: How SDC-1801 stands apart from brepocitinib
How SDC-1801 stands apart from brepocitinib Brepocitinib SDC-1801 Blood cell effects Clinically relevant reductions in No clinically relevant changes in key blood cells observed at blood cell counts at equivalent higher doses doses Kidney function Increases in a kidney function No changes in kidney
Slide 9: Dual TYK2/JAK1 inhibition more effective than single TYK2 or dual JAK1/2 inhibition in clinical studies
Dual TYK2/JAK1 inhibition more effective than single TYK2 or dual JAK1/2 inhibition in clinical studies % Patients achieving PASI-75 reduction in psoriasis after 12 weeks (PASI-75 = 75% improvement in psoriasis symptoms – a common clinical goal) In clinical trials, brepocitinib (a TYK2/JAK1 inhibito
Slide 10: SDC-1802: Cancer immunotherapy
SDC-1802: Cancer immunotherapy Immunomodulating molecule that has demonstrated good efficacy in preclinical models of cancer • Translational and additional preclinical studies have completed. • Experience in development of SDC-1801 supports process development of SDC-1802. • Increasingly strong pate
Slide 11: Expanding into CNS - targeting neuroinflammatory diseases
Expanding into CNS - targeting neuroinflammatory diseases Strong scientific rationale for Sareum's brain-penetrant Market opportunity TYK2/JAK1 inhibition in CNS compounds show promise Growing evidence that TYK2 Six compounds from proprietary Neuroinflammatory diseases affect inhibition plays a key
Slide 12: AI-powered discovery acceleration
AI-powered discovery acceleration About Announced August 2025: Initial 4-month partnership to optimise brain- penetrant TYK2/JAK1 inhibitors. Approach Receptor.AI will support this work using virtual screening and PK predictive models, and Sareum will oversee compound synthesis, testing, ADMET profi
Slide 13: Chk1 – SRA737
Chk1 – SRA737 Selective Chk1 kinase inhibitor Once daily oral administration Completed Phase 1/2
Slide 14: Validated science with broad potential applicability
Validated science with broad potential applicability VALIDATED SCIENCE COMMERCIAL POTENTIAL BROAD POTENTIAL APPLICABILITY Chk1 forms part of the DNA No approved Chk1 inhibitors Clinical and preclinical studies Damage Response (DDR) creates a first-in-class support the use of a selective pathway, a w
Slide 15: SRA737: Clinical-stage oncology asset with broad combination potential
SRA737: Clinical-stage oncology asset with broad combination potential • Selective Chk1 inhibitor targeting cancer cell replication stress and DNA damage repair pathways. • Two Phase 1/2 trials completed, funded by Sierra Oncology, showing good tolerability as monotherapy and in combination with che
Slide 16: Preliminary Financial Results
Preliminary Financial Results For the year ending 30 June 2025
Slide 17: Income statement
Income statement Financial results 2025 2024 for the year ended 30 June: (Unaudited) (Audited) £’000 £’000 Revenue -) - Administrative expenses (3,382) (4,596) Share of loss of associate 2) (60) Other operating income 240) 22) Operating loss (3,140) (4,634) Finance income 77) 32) Loss before taxatio
Slide 18: Balance sheet
Balance sheet Financial results 2025 2024 for the year ended 30 June: (Unaudited) (Audited) £’000 £’000 Non-current assets Property, plant and equipment -) -) Investment in associate -) 9) -) 9) Current assets Trade and other receivables 557) 1,299) Cash and cash equivalents 3,546) 1,459) 4,103) 2,7
Slide 19: Pipeline status and 2025 priorities
Pipeline status and 2025 priorities SDC-1801 • Positive Phase 1 data demonstrated a favourable safety and tolerability profile, pharmacokinetics supportive of once-daily dosing and dose- responsive PD biomarker reductions. • The 16-week GLP preclinical toxicology study was discontinued following une
Slide 20: Sareum Holdings plc
Sareum Holdings plc Unit 2A, Langford Arch London Road, Pampisford Cambridge CB22 3FX United Kingdom Tel: +44 (0) 1223 497700 Email: info@sareum.com 20